$ELVN
Enliven Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Burlingame, CA
ELVN chart
What traders are saying about $ELVN
Latest postsEnliven Therapeutics, Inc. news
- Enliven Therapeutics, Inc. Estimates – NASDAQ:ELVN
TradingView ·
- Enliven Therapeutics (ELVN) Holds Firm at $42.12 as Buyers Defend Support - MFI Overbought
https://www.siam.in/ ·
- Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock By Investing.com
Investing.com South Africa ·
- Enliven Therapeutics CFO Hohl sells $231,545 in shares
Investing.com ·
- Form 4 Enliven Therapeutics Inc: Benjamin Hohl (CFO) For: 19 October
Investing.com Canada ·
- After exercising options, Enliven Therapeutics (ELVN) CFO sells 6,018 shares under a trading plan.
Stock Titan ·
- Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Yahoo Finance ·
- Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML Strategy
Yahoo Finance ·
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharmadive.com ·
- Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Yahoo Finance ·
- Enliven Therapeutics to Present at Upcoming Investor Conferences
Yahoo Finance ·
- Miners And More Lead Slew Of Stocks To Watch — With This Line In Focus
Yahoo Finance ·
Enliven Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M |
| Diluted EPS | $-1.83 | $-1.89 | $-2.01 | $-12.05 |
| Total assets (year end) | $476.2M | $325.8M | $271.9M | $83.3M |
| Cash and equivalents (year end) | $98.9M | $124.1M | $100.1M | $75.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Enliven Therapeutics, Inc.
- Ticker
- ELVN (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Burlingame, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1672619
- Former names
- IMARA Inc.
Frequently asked questions
What exchange is Enliven Therapeutics, Inc. listed on?
Enliven Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ELVN.
What industry is Enliven Therapeutics, Inc. in?
Enliven Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc.'s business address on file with the SEC is in Burlingame, CA.
When does Enliven Therapeutics, Inc.'s fiscal year end?
Enliven Therapeutics, Inc.'s fiscal year ends on December 31.